Abstract:e15040 Background: NTRK fusions are actionable genomic alterations detected across tumor types. NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and paediatric tumour types. Here, we update the detection of NTRK gene fusions across tumor types and further describe fusion partner characteristics among Chinese patients. Methods: Samples submitted for clinical molecular profiling were retrospectively analyzed for NTRK fusion events. Method for identifying NTRK fusions was DNA-based next-generation sequencing that tumour DNA is extracted from formalin-fixed paraffin-embedded tissue. All NTRK fusion partners were identified for intact functional domains, domain prediction, breakpoints, frame retention and co-occurring alterations. Results: A total of 64 NTRK fusion events (0.26% of 24,451) were identified. NTRK fusions are characteristic in a few rare types of cancer, such as melanoma, glioma and carcinomas of the thyroid, lung and colon, but they are also infrequently seen in some uncommon cancers, such as secretory carcinoma of the breast or salivary gland and infantile fibrosarcoma. Among the fusions, NTRK1 (0.08% of 24,430), NTRK2 (0.02% of 24,445), NTRK3 (0.15% of 24,414) were identified. Twenty-six unique fusion partners were identified, the most common in NTRK1 fusion being TPM3 (23.8%), NTRK2 fusion being AGTPBP1 (33.3%), and NTRK3 fusion being TFG (13.5%). Almost 53.8 % (14 of 26) of all fusion events are expected to include the transmembrane domain contributed by the NTRK fusion partner. The most commonly identified breakpoints occur in exon 14 and exon 17 and in exon 15 and exon 20, in NTRK1, NTRK3, respectively. Conclusions: NTRK fusion products are diverse across tumor types, but the significance of these variations is not clear. The biological and clinical implications of retaining certain domains of NTRK and of fusion partners warrants further investigation.

Genomic characterization of the human trkC gene

Gene Expression of TrkC (NTRK3) in Human Soft Tissue Tumours.

The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma.

Molecular cloning and cellular localization of trkC in the chicken embryo

Molecular Characterization of the TrkA/NGF Receptor Minimal Enhancer Reveals Regulation by Multiple Cis Elements to Drive Embryonic Neuron Expression.

Disruption of the neurotrophin-3 receptor gene trkC eliminates la muscle afferents and results in abnormal movements

Identification and Expression Analysis of a Novel Splice Variant of Human Tumor Necrosis Factor Receptor Associated Factor 2

TrkAIII: A Novel Hypoxia-regulated Alternative TrkA Splice Variant of Potential Physiological and Pathological Importance

Expression and Prognostic Impact of NTF3 and TrkC in Hepatocellular Carcinoma.

Neuron , Volume 63 Supplemental Data CCM 2 Mediates Death Signaling by the TrkA Receptor Tyrosine Kinase

Expression of Tyrosine Kinase Receptor C in the Segments of the Spinal Cord and the Cerebral Cortex after Cord Transection in Adult Rats

Modifications in the C-terminal tail of TrkC significantly alter neurotrophin-3-promoted outgrowth of neurite-like processes from PC12 cells

Mklf7, a Potential Transcriptional Regulator of TrkA Nerve Growth Factor Receptor Expression in Sensory and Sympathetic Neurons.

Expression pattern of high-affinity tyrosine kinase Aduring the development of human fetal spinal cord

Brn3a Regulation of TrkA/NGF Receptor Expression in Developing Sensory Neurons.

Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene

Oncogenic role of a developmentally regulated NTRK2 splice variant

Genomic Organization of the Human C-Kit Gene - Evolution of the Receptor Tyrosine Kinase Subclass-Iii

The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

Tropomyosin Receptor Kinase B (trkb) Signalling: Targeted Therapy in Neurogenic Tumours

Characterization of NTRK gene fusion events in solid tumors among Chinese patients.